Brief: Regulus Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Lademirsen
24/02/2022 13:59
Feb 24 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
PHASE
2 CLINICAL TRIAL OF LADEMIRSEN FOR ALPORT SYNDROME
Source text for Eikon: ID:nPn8h6TPha
Further company coverage: RGLS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview